{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T02:02:54Z","timestamp":1780020174833,"version":"3.53.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T00:00:00Z","timestamp":1776470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"vor","delay-in-days":41,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China\u200c","doi-asserted-by":"crossref","award":["82303029"],"award-info":[{"award-number":["82303029"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Zhengzhou Science and Technology Innovation Project for Healthcare","award":["2024YLZDJH027"],"award-info":[{"award-number":["2024YLZDJH027"]}]},{"DOI":"10.13039\/501100011447","name":"Science and Technology Department of Henan Province","doi-asserted-by":"crossref","award":["232102311134"],"award-info":[{"award-number":["232102311134"]}],"id":[{"id":"10.13039\/501100011447","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-026-04980-8","type":"journal-article","created":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T08:17:06Z","timestamp":1776500226000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["PARP4 drives tumor progression by promoting glioma cell proliferation and invasion as a potential therapeutic target"],"prefix":"10.1007","volume":"17","author":[{"given":"Bingqi","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhou","family":"Jing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangyuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minghe","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ao","family":"Huo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenglin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongyu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wulong","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihua","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xudong","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,18]]},"reference":[{"key":"4980_CR1","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1158\/0008-5472.CAN-23-0024","volume":"83","author":"DB Zamler","year":"2023","unstructured":"Zamler DB, Hu J. Primitive oligodendrocyte precursor cells are highly susceptible to gliomagenic transformation. Cancer Res. 2023;83:807\u20138. https:\/\/doi.org\/10.1158\/0008-5472.CAN-23-0024.","journal-title":"Cancer Res"},{"key":"4980_CR2","doi-asserted-by":"publisher","first-page":"vi1","DOI":"10.1093\/neuonc\/noae145","volume":"26","author":"M Price","year":"2024","unstructured":"Price M, Ballard C, Benedetti J, Neff C, Cioffi G, Waite KA, et al. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2017\u20132021. Neuro Oncol. 2024;26:vi1-85. https:\/\/doi.org\/10.1093\/neuonc\/noae145.","journal-title":"Neuro Oncol"},{"key":"4980_CR3","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1200\/JCO.2003.05.063","volume":"21","author":"A Giese","year":"2003","unstructured":"Giese A, Bjerkvig R, Berens ME, Westphal M. Cost of migration: invasion of malignant gliomas and implications for treatment. J Clin Oncol. 2003;21:1624\u201336. https:\/\/doi.org\/10.1200\/JCO.2003.05.063.","journal-title":"J Clin Oncol"},{"key":"4980_CR4","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s00401-007-0293-7","volume":"114","author":"A Claes","year":"2007","unstructured":"Claes A, Idema AJ, Wesseling P. Diffuse glioma growth: a guerilla war. Acta Neuropathol. 2007;114:443\u201358. https:\/\/doi.org\/10.1007\/s00401-007-0293-7.","journal-title":"Acta Neuropathol"},{"key":"4980_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19041115","volume":"19","author":"C-A Liu","year":"2018","unstructured":"Liu C-A, Chang C-Y, Hsueh K-W, Su H-L, Chiou T-W, Lin S-Z, et al. Migration\/invasion of malignant gliomas and implications for therapeutic treatment. Int J Mol Sci. 2018;19:1115. https:\/\/doi.org\/10.3390\/ijms19041115.","journal-title":"Int J Mol Sci"},{"key":"4980_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-12751-3","volume":"24","author":"R Wei","year":"2024","unstructured":"Wei R, Zhou J, Bui B, Liu X. Glioma actively orchestrate a self-advantageous extracellular matrix to promote recurrence and progression. BMC Cancer. 2024;24:974. https:\/\/doi.org\/10.1186\/s12885-024-12751-3.","journal-title":"BMC Cancer"},{"key":"4980_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/biotech14020028","volume":"14","author":"EE Aitchison","year":"2025","unstructured":"Aitchison EE, Dimesa AM, Shoari A. Matrix metalloproteinases in glioma: drivers of invasion and therapeutic targets. Biotech. 2025;14:28. https:\/\/doi.org\/10.3390\/biotech14020028.","journal-title":"Biotech"},{"key":"4980_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2021.663092","author":"J-S So","year":"2021","unstructured":"So J-S, Kim H, Han K-S. Mechanisms of invasion in glioblastoma: extracellular matrix, Ca2+ signaling, and glutamate. Front Cell Neurosci. 2021. https:\/\/doi.org\/10.3389\/fncel.2021.663092.","journal-title":"Front Cell Neurosci"},{"key":"4980_CR9","doi-asserted-by":"publisher","unstructured":"Lodwick JE, Shen R, Erramilli S, Xie Y, Roganowicz K, Kossiakoff AA, et al. Structural Insights into the Roles of PARP4 and NAD + in the Human Vault Cage. bioRxiv. 2024. https:\/\/doi.org\/10.1101\/2024.06.27.601040.","DOI":"10.1101\/2024.06.27.601040"},{"key":"4980_CR10","doi-asserted-by":"publisher","first-page":"12492","DOI":"10.1093\/nar\/gkad1064","volume":"51","author":"L Frigon","year":"2023","unstructured":"Frigon L, Pascal JM. Structural and biochemical analysis of the PARP1-homology region of PARP4\/vault PARP. Nucleic Acids Res. 2023;51:12492\u2013507. https:\/\/doi.org\/10.1093\/nar\/gkad1064.","journal-title":"Nucleic Acids Res"},{"key":"4980_CR11","doi-asserted-by":"publisher","unstructured":"Frontiers | Beyond PARP1: The Potential of Other Members of the Poly (ADP-Ribose) Polymerase Family in DNA Repair and Cancer Therapeutics. https:\/\/doi.org\/10.3389\/fcell.2021.801200. Accessed 3 Dec 2025","DOI":"10.3389\/fcell.2021.801200"},{"key":"4980_CR12","doi-asserted-by":"publisher","unstructured":"Novel Biomarker Candidates for Colorectal Cancer Metastasis: A Meta-analysis of In Vitro Studies - Nguyen Phuoc Long, Wun Jun Lee, Nguyen Truong Huy, Seul Ji Lee, Jeong Hill Park, Sung Won Kwon, 2016. https:\/\/doi.org\/10.4137\/CIN.S40301. Accessed 3 Dec 2025","DOI":"10.4137\/CIN.S40301"},{"key":"4980_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-024-01328-1","volume":"16","author":"YF Lee","year":"2024","unstructured":"Lee YF, Phua CZJ, Yuan J, Zhang B, Lee MY, Kannan S, et al. PARP4 interacts with hnRNPM to regulate splicing during lung cancer progression. Genome Med. 2024;16:91. https:\/\/doi.org\/10.1186\/s13073-024-01328-1.","journal-title":"Genome Med"},{"key":"4980_CR14","doi-asserted-by":"publisher","first-page":"347","DOI":"10.5483\/BMBRep.2022-0202","volume":"56","author":"HY Sung","year":"2023","unstructured":"Sung HY, Han J, Chae YJ, Ju W, Kang JL, Park AK, et al. Identification of a novel PARP4 gene promoter CpG locus associated with cisplatin chemoresistance. BMB Rep. 2023;56:347\u201352. https:\/\/doi.org\/10.5483\/BMBRep.2022-0202.","journal-title":"BMB Rep"},{"key":"4980_CR15","doi-asserted-by":"publisher","first-page":"5314","DOI":"10.1128\/MCB.24.12.5314-5323.2004","volume":"24","author":"Y Liu","year":"2004","unstructured":"Liu Y, Snow BE, Kickhoefer VA, Erdmann N, Zhou W, Wakeham A, et al. Vault poly(ADP-ribose) polymerase is associated with mammalian telomerase and is dispensable for telomerase function and vault structure in vivo. Mol Cell Biol. 2004;24:5314\u201323. https:\/\/doi.org\/10.1128\/MCB.24.12.5314-5323.2004.","journal-title":"Mol Cell Biol"},{"key":"4980_CR16","doi-asserted-by":"publisher","first-page":"4426","DOI":"10.1038\/ncomms5426","volume":"5","author":"S Vyas","year":"2014","unstructured":"Vyas S, Matic I, Uchima L, Rood J, Zaja R, Hay RT, et al. Family-wide analysis of poly(ADP-ribose) polymerase activity. Nat Commun. 2014;5:4426. https:\/\/doi.org\/10.1038\/ncomms5426.","journal-title":"Nat Commun"},{"key":"4980_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-61981-x","volume":"16","author":"JE Lodwick","year":"2025","unstructured":"Lodwick JE, Shen R, Erramilli S, Xie Y, Roganowicz K, Ritchey S, et al. Structural insights into the roles of PARP4 and NAD+ binding in the human vault cage. Nat Commun. 2025;16:6724. https:\/\/doi.org\/10.1038\/s41467-025-61981-x.","journal-title":"Nat Commun"},{"key":"4980_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104588","volume":"206","author":"C-Y Hsu","year":"2025","unstructured":"Hsu C-Y, Pallathadka H, Jasim SA, Rizaev J, Olegovich Bokov D, Hjazi A, et al. Innovations in cancer immunotherapy: a comprehensive overview of recent breakthroughs and future directions. Crit Rev Oncol Hematol. 2025;206:104588. https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104588.","journal-title":"Crit Rev Oncol Hematol"},{"key":"4980_CR19","doi-asserted-by":"publisher","first-page":"vdad009","DOI":"10.1093\/noajnl\/vdad009","volume":"5","author":"P Sharma","year":"2023","unstructured":"Sharma P, Aaroe A, Liang J, Puduvalli VK. Tumor microenvironment in glioblastoma: current and emerging concepts. Neurooncol Adv. 2023;5:vdad009. https:\/\/doi.org\/10.1093\/noajnl\/vdad009.","journal-title":"Neurooncol Adv."},{"key":"4980_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17233777","volume":"17","author":"V Zoi","year":"2025","unstructured":"Zoi V, Galani V, Sioka C, Alexiou GA, Kyritsis AP. Immunotherapy for glioblastoma: a focus on PD-1\/PD-L1 inhibitors. Cancers (Basel). 2025;17:3777. https:\/\/doi.org\/10.3390\/cancers17233777.","journal-title":"Cancers (Basel)"},{"key":"4980_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1476565","author":"J Cao","year":"2024","unstructured":"Cao J, Liu C. Mechanistic studies of tumor-associated macrophage immunotherapy. Front Immunol. 2024. https:\/\/doi.org\/10.3389\/fimmu.2024.1476565.","journal-title":"Front Immunol"},{"key":"4980_CR22","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.70412","volume":"6","author":"H Chen","year":"2025","unstructured":"Chen H, Yang H, Guo L, Sun Q. The role of immune checkpoint inhibitors in cancer therapy: mechanism and therapeutic advances. MedComm. 2025;6:e70412. https:\/\/doi.org\/10.1002\/mco2.70412.","journal-title":"MedComm"},{"key":"4980_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci12050544","volume":"12","author":"AF Haddad","year":"2022","unstructured":"Haddad AF, Young JS, Morshed RA, Berger MS. FLAIRectomy: resecting beyond the contrast margin for glioblastoma. Brain Sci. 2022;12:544. https:\/\/doi.org\/10.3390\/brainsci12050544.","journal-title":"Brain Sci"},{"key":"4980_CR24","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1001\/archneurol.2011.2910","volume":"69","author":"F Sahm","year":"2012","unstructured":"Sahm F, Capper D, Jeibmann A, Habel A, Paulus W, Troost D. Addressing diffuse glioma as a systemic brain disease with single-cell analysis. Arch Neurol. 2012;69:523\u20136. https:\/\/doi.org\/10.1001\/archneurol.2011.2910.","journal-title":"Arch Neurol"},{"key":"4980_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-022-03468-7","volume":"20","author":"Y Li","year":"2022","unstructured":"Li Y, Pan M, Lu T, Yu D, Liu C, Wang Z, et al. RAF1 promotes lymphatic metastasis of hypopharyngeal carcinoma via regulating LAGE1: an experimental research. J Transl Med. 2022;20:255. https:\/\/doi.org\/10.1186\/s12967-022-03468-7.","journal-title":"J Transl Med"},{"key":"4980_CR26","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S205333","volume":"12","author":"J Liu","year":"2019","unstructured":"Liu J, Liu D, Yang Z, Yang Z. High LAMC1 expression in glioma is associated with poor prognosis. OncoTargets Ther. 2019;12:4253. https:\/\/doi.org\/10.2147\/OTT.S205333.","journal-title":"OncoTargets Ther"},{"key":"4980_CR27","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.5873","volume":"12","author":"X Xu","year":"2023","unstructured":"Xu X, Shen L, Li W, Liu X, Yang P, Cai J. ITGA5 promotes tumor angiogenesis in cervical cancer. Cancer Med. 2023;12:11983. https:\/\/doi.org\/10.1002\/cam4.5873.","journal-title":"Cancer Med"},{"key":"4980_CR28","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1080\/15384101.2023.2205204","volume":"22","author":"C Qi","year":"2023","unstructured":"Qi C, Lei L, Hu J, Ou S. Establishment and validation of a novel integrin-based prognostic gene signature that sub-classifies gliomas and effectively predicts immunosuppressive microenvironment. Cell Cycle. 2023;22:1259\u201383. https:\/\/doi.org\/10.1080\/15384101.2023.2205204.","journal-title":"Cell Cycle"},{"key":"4980_CR29","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s12964-023-01338-3","volume":"22","author":"C Su","year":"2024","unstructured":"Su C, Mo J, Dong S, Liao Z, Zhang B, Zhu P. Integrin\u03b2-1 in disorders and cancers: molecular mechanisms and therapeutic targets. Cell Commun Signal. 2024;22:71. https:\/\/doi.org\/10.1186\/s12964-023-01338-3.","journal-title":"Cell Commun Signal"},{"key":"4980_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.844144","volume":"12","author":"S Li","year":"2022","unstructured":"Li S, Zhang N, Liu S, Zhang H, Liu J, Qi Y, et al. ITGA5 is a novel oncogenic biomarker and correlates with tumor immune microenvironment in gliomas. Front Oncol. 2022;12:844144. https:\/\/doi.org\/10.3389\/fonc.2022.844144.","journal-title":"Front Oncol"},{"key":"4980_CR31","first-page":"138","volume":"11","author":"J Zhou","year":"2021","unstructured":"Zhou J, Wang H, Hong F, Hu S, Su X, Chen J, et al. CircularRNA circPARP4 promotes glioblastoma progression through sponging miR-125a-5p and regulating FUT4. Am J Cancer Res. 2021;11:138.","journal-title":"Am J Cancer Res"},{"key":"4980_CR32","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1093\/neuonc\/nox044","volume":"19","author":"RS McNeill","year":"2017","unstructured":"McNeill RS, Canoutas DA, Stuhlmiller TJ, Dhruv HD, Irvin DM, Bash RE, et al. Combination therapy with potent PI3K and MAPK inhibitors overcomes adaptive kinome resistance to single agents in preclinical models of glioblastoma. Neuro Oncol. 2017;19:1469. https:\/\/doi.org\/10.1093\/neuonc\/nox044.","journal-title":"Neuro Oncol"},{"key":"4980_CR33","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-3389","author":"HA Luchman","year":"2014","unstructured":"Luchman HA, Stechishin OD, Nguyen SA, Lun XQ, Cairncross JG, Weiss S. Dual mTORC1\/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival. Clin Cancer Res. 2014. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-3389.","journal-title":"Clin Cancer Res"},{"key":"4980_CR34","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1038\/bjc.2012.368","volume":"107","author":"A Naing","year":"2012","unstructured":"Naing A, Aghajanian C, Raymond E, Olmos D, Schwartz G, Oelmann E, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma. Br J Cancer. 2012;107:1093\u20139. https:\/\/doi.org\/10.1038\/bjc.2012.368.","journal-title":"Br J Cancer"},{"key":"4980_CR35","doi-asserted-by":"publisher","first-page":"R12","DOI":"10.1186\/bcr3604","volume":"16","author":"NJ Jordan","year":"2014","unstructured":"Jordan NJ, Dutkowski CM, Barrow D, Mottram HJ, Hutcheson IR, Nicholson RI, et al. Impact of dual mTORC1\/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro. Breast Cancer Res. 2014;16:R12. https:\/\/doi.org\/10.1186\/bcr3604.","journal-title":"Breast Cancer Res"},{"key":"4980_CR36","doi-asserted-by":"publisher","first-page":"5429","DOI":"10.2147\/OTT.S254995","volume":"13","author":"Y Zhao","year":"2020","unstructured":"Zhao Y, Li Y, Zhang R, Wang F, Wang T, Jiao Y. The role of erastin in ferroptosis and its prospects in cancer therapy. Onco Targets Ther. 2020;13:5429. https:\/\/doi.org\/10.2147\/OTT.S254995.","journal-title":"Onco Targets Ther"},{"key":"4980_CR37","doi-asserted-by":"publisher","first-page":"4761","DOI":"10.1038\/s41598-019-41182-5","volume":"9","author":"D Stakheev","year":"2019","unstructured":"Stakheev D, Taborska P, Strizova Z, Podrazil M, Bartunkova J, Smrz D. The WNT\/\u03b2-catenin signaling inhibitor XAV939 enhances the elimination of LNCaP and PC-3 prostate cancer cells by prostate cancer patient lymphocytes in vitro. Sci Rep. 2019;9:4761. https:\/\/doi.org\/10.1038\/s41598-019-41182-5.","journal-title":"Sci Rep"},{"key":"4980_CR38","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.02523","volume":"3","author":"SJ Dixon","year":"2014","unstructured":"Dixon SJ, Patel DN, Welsch M, Skouta R, Lee ED, Hayano M, et al. Pharmacological inhibition of cystine-glutamate exchange induces endoplasmic reticulum stress and ferroptosis. Elife. 2014;3:e02523. https:\/\/doi.org\/10.7554\/eLife.02523.","journal-title":"Elife"},{"key":"4980_CR39","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1038\/s41598-018-19213-4","volume":"8","author":"M Sato","year":"2018","unstructured":"Sato M, Kusumi R, Hamashima S, Kobayashi S, Sasaki S, Komiyama Y, et al. The ferroptosis inducer erastin irreversibly inhibits system xc\u2212 and synergizes with cisplatin to increase cisplatin\u2019s cytotoxicity in cancer cells. Sci Rep. 2018;8:968. https:\/\/doi.org\/10.1038\/s41598-018-19213-4.","journal-title":"Sci Rep"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-026-04980-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-04980-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-04980-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T01:21:43Z","timestamp":1780017703000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-026-04980-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,18]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4980"],"URL":"https:\/\/doi.org\/10.1007\/s12672-026-04980-8","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,18]]},"assertion":[{"value":"4 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Committee of the Fifth Affiliated Hospital of Zhengzhou University (Approval No.\u202fKY2025054; approval date: 16 October 2025). Archived human glioma frozen tissue samples used in this study were originally collected under informed consent (or broad consent) from patients (or their legal guardians), allowing future use of residual specimens for research. All procedures involving human tissue were carried out in accordance with the 1964 Declaration of Helsinki and its later amendments (or comparable ethical standards).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable\u2014no identifiable individual patient data are included in the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"813"}}